Find out more about Pilar Dominguez Rodriguez' experience
Pilar Dominguez Rodriguez' highlights
Displaying the 3 most recent scholarly works by Pilar Dominguez Rodriguez.
CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory.
Emily J Lelliott, Isabella Y Kong, Magnus Zethoven, Kelly M Ramsbottom, Luciano G Martelotto, Deborah Meyran, Joe Jiang Zhu, Matteo Costacurta, Laura Kirby, Jarrod J Sandow, Lydia Lim, Pilar M Dominguez, Izabela Todorovski, Nicole M Haynes, Paul A Beavis, Paul J Neeson, Edwin D Hawkins, Grant A McArthur, Ian A Parish, Ricky W Johnstone, et al.
Journal article | 2021 | Cancer Discov
Pharmacological inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor-positive br..
Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit
Jessica Salmon, Izabela Todorovski, Stephin Vervoort, Kym Stanley, Conor Kearney, Luciano Martelotto, Fernando Rossello, Tim Semple, Gisela Mir-Arnau, Magnus Zethoven, Michael Bots, Eva Vidacs, Kate McArthur, Elise Gressier, Nicky de Weerd, Jens Lichte, Madison Kelly, Leonie Cluse, Simon Hogg, Paul Hertzog, et al.
Journal article | 2020
Pharmacological inhibition of epigenetic enzymes can have therapeutic benefit, particularly against hematological malignancies. Wh..
TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis
Wojciech Rosikiewicz, Xiaowen Chen, Pilar M Dominguez, Hussein Ghamlouch, Said Aoufouchi, Olivier A Bernard, Ari Melnick, Sheng Li
Journal article | 2020 | SCIENCE ADVANCES
The TET2 DNA hydroxymethyltransferase is frequently disrupted by somatic mutations in diffuse large B cell lymphomas (DLBCLs), a t..
The Sir Peter MacCallum Department of Oncology